Group 1 - Recent leadership changes and strategic adjustments have occurred in several multinational pharmaceutical companies, including Takeda, Merck, Novo Nordisk, and Johnson & Johnson [2][3] - Takeda's China division president, Shan Guohong, announced his departure to seek external opportunities, with Liu Yan appointed as the acting president [2] - Liu Yan, who joined Takeda in 2021, will take full responsibility for the strategic and operational management of Takeda China starting July 1, 2025 [2] Group 2 - Johnson & Johnson's China vice president and chief digital officer, Dai Ying, will leave the company on June 30, 2023, to pursue external opportunities [3] - Merck announced that Anna Van Acker, its global senior vice president and president of Merck China, will step down from her role, with Kyle Tattle taking over as president of Merck China [3] - Novo Nordisk's CEO, Jørgensen, will resign after eight years due to recent market challenges and stock price fluctuations, but will remain temporarily to assist with the transition [3]
武田中国总裁单国洪月底离职，跨国药企高管变动频繁｜快讯
Hua Xia Shi Bao·2025-06-17 06:49